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Assessing the impact of genomic alterations on pro-
tein networks is fundamental in identifying the mech-
anisms that shape cancer heterogeneity. We have
used isobaric labeling to characterize the proteomic
landscapes of 50 colorectal cancer cell lines and to
decipher the functional consequences of somatic
genomic variants. The robust quantification of over
9,000 proteins and 11,000 phosphopeptides on
average enabled the de novo construction of a func-
tional protein correlation network, which ultimately
exposed the collateral effects of mutations on pro-
tein complexes. CRISPR-cas9 deletion of key chro-
matin modifiers confirmed that the consequences
of genomic alterations can propagate through pro-
tein interactions in a transcript-independent manner.
Lastly, we leveraged the quantified proteome to
perform unsupervised classification of the cell lines
and to build predictive models of drug response
in colorectal cancer. Overall, we provide a deep
integrative view of the functional network and the
molecular structure underlying the heterogeneity of
colorectal cancer cells.
INTRODUCTION
Tumors exhibit a high degree of molecular and cellular heteroge-
neity due to the impact of genomic aberrations on protein
networks underlying physiological cellular activities. Modern
mass-spectrometry-based proteomic technologies have the
capacity to perform highly reliable analytical measurements ofCell Re
This is an open access article undproteins in large numbers of subjects and analytes, providing a
powerful tool for the discovery of regulatory associations be-
tween genomic features, gene expression patterns, protein net-
works, and phenotypic traits (Mertins et al., 2016; Zhang et al.,
2014, 2016). However, understanding how genomic variation
affects protein networks and leads to variable proteomic land-
scapes and distinct cellular phenotypes remains challenging
due to the enormous diversity in the biological characteristics
of proteins. Studying protein co-variation holds the promise to
overcome the challenges associated with the complexity of pro-
teomic landscapes as it enables grouping of multiple proteins
into functionally coherent groups and is now gaining ground in
the study of protein associations (Stefely et al., 2016; Wang
et al., 2017). Colorectal cancer cell lines are widely used as
cancer models; however, their protein and phosphoprotein co-
variation networks and the genomic factors underlying their
regulation remain largely unexplored.
Here, we studied a panel of 50 colorectal cancer cell lines
(colorectal adenocarcinoma [COREAD]) using isobaric labeling
and tribrid mass spectrometry proteomic analysis in order to
assess the impact of somatic genomic variants on protein net-
works. This panel has been extensively characterized by
whole-exome sequencing, gene expression profiling, copy num-
ber and methylation profiling, and the frequency of molecular
alterations is similar to that seen in clinical colorectal cohorts
(Iorio et al., 2016). First, we leveraged the robust quantification
of over 9,000 proteins to build de novo protein co-variation
networks, and we show that they are highly representative of
known protein complexes and interactions. Second, we ratio-
nalize the impact of genomic variation in the context of the can-
cer cell protein co-variation network (henceforth, ‘‘co-variome’’)
to uncover protein network vulnerabilities. Proteomic and RNA
sequencing (RNA-seq) analysis of human induced pluripotent
stem cells (iPSCs) engineered with gene knockouts of keyports 20, 2201–2214, August 29, 2017 ª 2017 The Author(s). 2201
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
chromatin modifiers confirmed that genomic variation can be
transmitted fromdirectly affected proteins to tightly co-regulated
distant gene products through protein interactions. Overall, our
results constitute an in-depth view of the molecular organization
of colorectal cancer cells widely used in cancer research.
RESULTS
Quantified Proteome and Phosphoproteome Coverage
and Correlation with Gene Expression
To assess the variation in protein abundance and phosphoryla-
tion within a panel of 50 colorectal cancer cell lines (COREAD),
we utilized isobaric peptide labeling (TMT-10plex) and MS3
quantification (Figure S1A). We obtained relative quantification
between the different cell lines (scaled intensities range:
0–1,000) for an average of 9,410 proteins and 11,647 phospho-
peptides (Tables S1 and S2; Figure S1B). To assess the repro-
ducibility of our data, we computed the coefficient of variation
(CV) (CV = SD/mean) of protein abundances for 11 cell lines
measured as biological replicates. The median CV in our study
was 10.5%, showing equivalent levels of intra-laboratory bio-
logical variation with previously published TMT data for seven
colorectal cancer cell lines (McAlister et al., 2014; Figure S1C).
Inter-laboratory comparison for the 7 cell lines common in both
studies showedmedian CV = 13.9% (Figure S1C). The additional
variation encompasses differences in sample preparation
methods (e.g., digestion enzymes), mass spectrometry instru-
mentation, and raw signal processing. The same SW48 protein
digest aliquoted in two parts and labeled with two different
TMT labels within the same 10plex experiment displayed a
median CV = 1.9% (Figure S1C), indicating that the labeling pro-
cedure and the mass spectrometry (MS) signal acquisition noise
have very small contribution to the total variation. The protein
abundance profiles for 11 cell lines measured as biological
replicates in two separate sets are shown as a heatmap in
Figure S1D, revealing the high heterogeneity of the COREAD
proteomic landscapes. The variation between different cell lines
was on average 3 times higher than the variation between
replicates (Figure S1E), with 93% of the proteins exhibiting an
inter-sample variation greater than the respective baseline vari-
ation between replicates. For proteins participating in basic
cellular processes (selected Kyoto encyclopedia of genes and
genomes [KEGG] pathways), the median CV between biological
replicates was as low as 8% (Figure S1F). At the phosphopeptide
level, the SW48 biological replicates across all multiplex sets
displayed amedian CV = 22% (Figure S1G), reflecting the gener-
ally higher uncertainty of the peptide level measurements
compared to the protein level measurements. Taken together,
our results show that protein abundance differences as low as
50% or 1.5-fold (>2 3 CV%) can be reliably detected using our
proteomics approach at both the proteome and phosphopro-
teome level.
Qualitatively, phosphorylated proteins (n = 3,565) were highly
enriched for spliceosomal and cell cycle functions and covered
a wide range of cancer-related pathways (Figure S2A). The
phosphosites were comprised of 86% serine, 13% threonine,
and <1% tyrosine phosphorylation (Figure S2B), and the most
frequent motifs identified were pS-P (47% of all pS) and pT-P2202 Cell Reports 20, 2201–2214, August 29, 2017(63%of all pT) (Figure S2C). Approximately 70%of the quantified
phosphorylation sites are cataloged in Uniprot, and 751 of these
represent known kinase substrates in the PhosphoSitePlus
database (Hornbeck et al., 2015). In terms of phosphorylation
quantification, we observed that phosphorylation profiles were
strongly correlated with the respective protein abundances
(Figure S2D), and therefore, to detect net phosphorylation
changes, we corrected the phosphorylation levels for total
protein changes by linear regression.
Correlation analysis between mRNA (publicly available micro-
array data) and relative protein abundances for each gene
across the cell lines indicated a pathway-dependent con-
cordance of protein/mRNA expression with median Pearson’s
r = 0.52 (Figure S2E). Highly variable mRNAs tend to correspond
to highly variable proteins (Spearman’s r = 0.62), although with a
wide distribution (Figure S2F). Notably, several genes, including
TP53, displayed high variation at the protein level despite the low
variation at the mRNA level, implicating significant post-tran-
scriptional modulation of their abundance.
Our COREAD proteomics and phosphoproteomics data
can be downloaded from ftp://ngs.sanger.ac.uk/production/
proteogenomics/WTSI_proteomics_COREAD/ in annotated
*.gct, *.gtf, and *.bb file formats compatible with the Integrative
Genomics Viewer (Robinson et al., 2011), the Morpheus clus-
tering web tool (https://software.broadinstitute.org/morpheus/),
or the Ensembl (Aken et al., 2017) and University of California
Santa Cruz (UCSC) (Kent et al., 2002) genome browsers. Our
proteomics data can also be viewed through the Expression
Atlas database (Petryszak et al., 2016).
The Subunits of Protein Complexes Tightly Maintain
Their Total Abundance Ratios Post-transcriptionally
The protein abundance measurements allowed us to study the
extent to which proteins tend to be co-regulated in abundance
across the colorectal cancer cell lines. We first computed the
Pearson’s correlation coefficients between proteins with known
physical interactions in protein complexes cataloged in the
CORUM database (Ruepp et al., 2010). We found that the distri-
bution of correlations between CORUM protein pairs was
bimodal and clearly shifted to positive values (Wilcoxon test; p
value < 2.2e16) with mean 0.33 (Figure 1A, left panel), whereas
all pairwise protein-to-protein correlations displayed a normal
distribution with mean 0.01 (Figure 1A, left panel). Specifically,
290 partially overlapping CORUM complexes showed a greater
than 0.5 median correlation between their subunits (Table S3).
It has been shown that high-stoichiometry interactors are more
likely to be coherently expressed across different cell types
(Hein et al., 2015); therefore, our correlation data offer an assess-
ment of the stability of known protein complexes in the context of
colorectal cancer cells. Moreover, less stable or context-depen-
dent interactions in known protein complexes may be identified
by outlier profiles. Such proteins, with at least 50% lower individ-
ual correlation compared to the average complex correlation, are
highlighted in Table S3. For example, the ORC1 and ORC6
proteins displayed a divergent profile from the average profile
of the ORC complex, which is in line with their distinct roles in
the replication initiation processes (Ohta et al., 2003; Prasanth
et al., 2002).
Figure 1. Global Distributions of Gene-to-Gene Correlations and Protein Co-variation Networks in Colorectal Cancer Cell Lines
(A) Distributions of Pearson’s correlation coefficients between protein-protein pairs (left panel) andmRNA-mRNA pairs (right panel) for all pairs (gray) and for pairs
with known interactions in the CORUM database (blue).
(B) Receiver operating characteristic (ROC) curves illustrating the performance of proteomics- and transcriptomics-based correlations to predict CORUM and
high-confident STRING interactions.
(C) Protein abundance correlation networks derived fromWGCNA analysis for enriched CORUM complexes. The nodes are color-coded according to mRNA-to-
protein Pearson correlation.
(D) The global structure of the WGCNA network using modules with more than 50 nodes. Protein modules are color coded according to the WGCNA module
default name, and representative enriched terms are used for the annotation of the network.
See also Figure S3.In contrast, the distribution of Pearson’s coefficients between
CORUM pairs based on mRNA co-variation profiles was only
slightly shifted toward higher correlations with mean = 0.096
(Figure 1A, right panel). Interestingly, proteins with strong corre-
lations within protein complexes showed low variation across
the COREAD panel (Figure S2G) and have poor correspondence
to mRNA levels (Figure S2H). Together, these suggest that the
subunits of most of the known protein complexes are regulated
post-transcriptionally to accurately maintain stable ratio of total
abundance. Receiver operating characteristic (ROC) analyses
confirmed that our proteomics data outperformed mRNA data
in predicting protein complexes as well as high confident
STRING interactions (Szklarczyk et al., 2015; CORUM ROC
area under the curve [AUC]: 0.79 versus 0.61; STRING ROC
AUC: 0.71 versus 0.61; for proteomics and gene expression,
respectively; Figure 1B). The ability to also predict any type of
STRING interaction suggests that protein co-variation also en-
compasses a broader range of functional relationships beyond
structural physical interactions. Overall, our results demonstratethat correlation analysis of protein abundances across a limited
set of cellular samples with variable genotypes can generate co-
variation signatures for many known protein-protein interactions
and protein complexes.
The Colorectal Cancer Cell Protein Correlation Network
We conducted a systematic un-biased genome-wide analysis to
characterize the colorectal cancer cell protein-protein correla-
tion network and to identify de novo modules of interconnected
proteins. To this end, we performed a weighted correlation
network analysis (WGCNA) (Langfelder and Horvath, 2008) using
8,295 proteins quantified in at least 80% of the cell lines. A total
of 284 protein modules ranging in size from 3 to 1,012 proteins
(Q1 = 6; Q3 = 18) were inferred covering the entire input dataset.
An interaction weight was assigned to each pair of correlating
proteins based on their profile similarities and the properties of
the network. We performed Gene Ontology annotation of the
modules with the WGCNA package as well as using additional
terms from CORUM, KEGG, GOBP-slim, GSEA, and PfamCell Reports 20, 2201–2214, August 29, 2017 2203
databases with a Fisher’s exact test (Benjamini-Hochberg [Benj.
Hoch.] false discovery rate [FDR] < 0.05). We found significantly
enriched terms for 235 modules (Table S4) with an average
annotation coverage of 40%. Specifically, 111 modules dis-
played overrepresentation of CORUM protein complexes. For
29 of the 49 not-annotated modules, we detected known
STRING interactions within each module, suggesting that these
also capture functional associations that do not converge to
specific terms.
The correlation networks of protein complexes with more than
2 nodes are shown in Figure 1C. The global structure of the
colorectal cancer network comprised of modules with at least
50 proteins is depicted in Figure 1D and is annotated by signifi-
cant terms. The entire WGCNA network contains 87,420 interac-
tions (weight > 0.02; 96% positive; mean Pearson’s r = 0.61),
encompassing 7,248 and 20,969 known CORUM and STRING
interactions of any confidence, respectively. Overlaying the
protein abundance levels on the network generates a unique
quantitative map of the cancer cell co-variome, which can help
discriminate the different biological characteristics of the cell
lines (Figure S3A). For instance, it can be inferred that the
CL-40 cell line is mainly characterized by low abundances of
cell cycle, ribosomal, and RNA metabolism proteins, which
uniquely coincide with increased abundances of immune
response proteins (Figure S3A). The full WGCNA network with
weights greater than 0.02 is provided in Table S5.
As most of the proteins in modules representing protein com-
plexes are poorly correlatedwithmRNA levels, we next sought to
understand the transcriptional regulation of the modules with the
highest mean mRNA-to-protein correlations (5th quantile; mean
Pearson’s r > 0.57; 41 modules; 1,497 proteins). These included
several large components of the co-variome (e.g., ‘‘cell adhe-
sion,’’ ‘‘small molecule metabolic process,’’ and ‘‘innate immune
response’’), modules showing enrichment for experimental gene
sets (based on gene set enrichment analysis [GSEA]), and mod-
ules containing proteins encoded by common chromosomal
regions, implicating the effects of DNA copy number variations
(Figure S3B). In order to further annotate the modules with
potential transcriptional regulators, we examined whether
transcription factors that are members of the large transcription-
ally regulated modules are co-expressed along with their target
genes at the protein level. Transcription factor enrichment
analysis (Kuleshov et al., 2016) indicated that the ‘‘xenobiotic
and small molecule metabolic process’’ module was enriched
for the transcription factors HNF4A and CDX2 and that
STAT1/STAT2 were the potential master regulators of the ‘‘im-
mune response’’ module (Figure S3B, top left panel). HNF4A
(hepatocyte nuclear factor 4-alpha) is an important regulator of
metabolism, cell junctions, and the differentiation of intestinal
epithelial cells (Garrison et al., 2006) and has been previously
associated with colorectal cancer proteomic subtypes in human
tumors analyzed by the CPTAC consortium (Zhang et al., 2014).
Here, we were able to further characterize the consequences of
HNF4A variation through its proteome regulatory network.
To globally understand the interdependencies of protein
complexes in the colorectal cancer cells, we plotted the mod-
ule-to-module relationships as a correlation heatmap using
only modules enriched for protein complexes. The representa-2204 Cell Reports 20, 2201–2214, August 29, 2017tive profile of each module (eigengene or first principal com-
ponent; Langfelder and Horvath, 2007) was used as a metric
(Figure S3C). This analysis captures known functional associa-
tions between protein complexes (e.g., MCM-ORC, spliceo-
some-polyadenylation, and THO-nuclear pore; Lei and Tye,
2001; Millevoi et al., 2006; Wickramasinghe and Laskey, 2015)
and reveals the higher order organization of the proteome. The
major clusters of the correlation map can be categorized into
three main themes: (1) gene expression/splicing/translation/cell
cycle; (2) protein processing and trafficking; and (3) mitochon-
drial functions. This demonstrates that such similarity profiling
of abundance signatures has the potential to uncover novel in-
stances of cross-talk between protein complexes and also to
discriminate sub-complexes within larger protein assemblies.
In addition to protein abundance co-variation, the scale of
global phosphorylation survey accomplished here offers the op-
portunity for the de novo prediction of kinase-substrate associ-
ations inferred by co-varying phosphorylation patterns that
involve kinases (Ochoa et al., 2016; Petsalaki et al., 2015). Cor-
relation analysis among 436 phosphopeptides attributed to
137 protein kinases and 29 protein phosphatases yielded 186
positive and 40 negative associations at Benj. Hoch. FDR < 0.1
(Figure S4A), representing the co-phosphorylation signature of
kinases and phosphatases in the COREAD panel. Using this
high-confidence network as the baseline, we next focused on
co-phosphorylation profiling of kinases and phosphatases
involved in KEGG signaling pathways (Figure S4B), where known
kinase relationships can be used to assess the validity of the
predictions. We found co-regulated phosphorylation between
RAF1, MAPK1, MAPK3, and RPS6KA3, which were more
distantly correlated with the co-phosphorylated BRAF and
ARAF protein kinases, all members of the mitogen-activated
protein kinase (MAPK) pathway core axis (Figure S4B).
MAP2K1 (or MEK1) was found phosphorylated at T388 (un-
known kinase substrate), which was not correlating with the
above profile. The S222 phosphorylation site of MAP2K2 (or
MEK2), regulated by RAF kinase, was not detected possibly
due to limitations related to the lengthy (22 amino acids) theoret-
ical overlapping peptide. Strongly maintained co-phosphoryla-
tion between CDK1, CDK2, and CDK7 of the cell cycle pathway
was another true positive example (Figure S4B). The correlation
plots of MAPK1 and MAPK3 phosphorylation and total protein
are depicted in Figure S4C, top panel. The co-phosphorylation
of BRAF and ARAF is depicted in Figure S4C, bottom left panel.
A negative correlation example (between CDK1 kinase and
PPP2R5D phosphatase), reflecting the known role of PPP2R5D
as an upstream negative regulator of CDK1 (Forester et al.,
2007), is shown in Figure S4C, bottom right panel.
Taken together, our correlation analyses reveal the higher-
order organization of cellular functions. This well-organized
structure is shaped by the compartmental interactions between
protein complexes, and it is clearly divided into transcriptionally
and post-transcriptionally regulated sectors. The analysis per-
formed here constitutes a reference point for the better under-
standing of the underlying biological networks in the COREAD
panel. The resolution and specificity of the protein clusters can
be further improved by the combinatorial use of alternative algo-
rithms for construction of biological networks (Allen et al., 2012).
Figure 2. The Effect of Colorectal Cancer Driver Mutations on Protein Abundances
(A) Association of driver mutations in colorectal cancer genes with the respective protein abundance levels (ANOVA test; permutation-based FDR < 0.1). The cell
lines are ranked by highest (left) to lowest (right) protein abundance, and the bar on the top indicates the presence of driver mutations with black marks.
(B) Volcano plot summarizing the effect of loss of function (LoF) and missense driver mutations on the respective protein abundances.Similarly, correlation analysis of protein phosphorylation data
demonstrates that functional relationships are encrypted in pat-
terns of co-regulated or anti-regulated phosphorylation events.
The Impact of Genomic Alterations on Protein
Abundance
Assessing the impact of non-synonymous protein coding vari-
ants and copy number alterations on protein abundance is
fundamental in understanding the link between cancer geno-
types and dysregulated biological processes. To characterize
the impact of genomic alterations on the proteome of the CO-
READ panel, we first examined whether driver mutations in the
most frequently mutated colorectal cancer driver genes (Iorio
et al., 2016) could alter the levels of their protein products. For
10 out of 18 such genes harboring driver mutations in at least 5
cell lines (PTEN, PIK3R1, APC, CD58, B2M, ARID1A, BMPR2,
SMAD4, MSH6, and EP300), we found a significant negative
impact on the respective protein abundances, in line with their
function as tumor suppressors, whereas missense mutations in
TP53 were associated with elevated protein levels as previously
reported (Bertorelle et al., 1996; Dix et al., 1994; ANOVA test;
permutation-based FDR < 0.1; Figure 2A). For the majority of
driver mutations in oncogenes, there was no clear relationship
between the presence of mutations and protein expression (Fig-
ure 2B). From these observations, we conclude that mutations in
canonical tumor suppressor genes predicted to cause
nonsense-mediated decay of transcript generally result in a
decrease of protein abundance. This effect, however, varies be-
tween the cell lines.
We extended our analysis to globally assess the effect of
mutations on protein abundances. For 4,658 genes harboringsomatic single-amino-acid substitutions in at least three cell
lines, only 12 proteins exhibited differential abundances in the
mutated versus the wild-type cell lines at ANOVA test FDR <
0.1 (Figure 3A). Performing the analysis in genes with loss-of-
function (LoF) mutations (frameshift, nonsense, in-frame, splice
site, and start-stop codon loss) showed that 115 out of the 957
genes tested presented lower abundances in the mutated
versus the wild-type cell lines at ANOVA test FDR < 0.1 (Fig-
ure 3B). The STRING network of the top significant hits is
depicted in Figure 3C and indicates that many of the affected
proteins are functionally related. Overall, almost all proteins in
a less stringent set with p value < 0.05 (n = 217) were found
to be downregulated by LoF mutations, confirming the general
negative impact on protein abundances. As expected, zygosity
of LoF mutations was a major determinant of protein abun-
dance, with homozygous mutations imposing a more severe
downregulation compared to heterozygous mutations (Fig-
ure 3D). Whereas the negative impact of LoF mutations was
not biased toward their localization in specific protein domains
(Figure S5A), we found that mutations localized closer to the
protein C terminus were slightly less detrimental (Figure S5B).
Notably, genes with LoF mutations and subsequently the signif-
icantly affected proteins displayed an overrepresentation of
chromatin modification proteins over the identified proteome
as the reference set (Fisher’s exact test; Benj. Hoch. FDR <
0.05). Chromatin modifiers play an important role in the regula-
tion of chromatin structure during transcription, DNA replica-
tion, and DNA repair (Narlikar et al., 2013). Impaired function
of chromatin modifiers can lead to dysregulated gene expres-
sion and cancer (Cairns, 2001). Our results show that loss of
chromatin modification proteins due to the presence of LoFCell Reports 20, 2201–2214, August 29, 2017 2205
Figure 3. The Global Effects of Genomic Alterations on Protein and mRNA Abundances
(A) Volcano plot summarizing the effect of missense mutations on the respective protein abundances (ANOVA test). Hits at permutation-based FDR < 0.1 are
colored.
(B) Volcano plot summarizing the effect of LoF mutations on the respective protein abundances (ANOVA test). Hits at permutation-based FDR < 0.1 are colored.
(C) STRING network of the proteins downregulated by LoF mutations at FDR < 0.1.
(D) Boxplots illustrating the protein abundance differences between all proteins and proteins with heterozygous or homozygous LoF mutations.
(E) Volcano plot summarizing the effect of LoF mutations with both mRNA and protein measurements on the respective mRNA abundances (ANOVA test). Hits at
permutation-based FDR < 0.1 are colored.
(F) Venn diagram displaying the overlap between proteins and mRNAs affected by LoF mutations. Selected unique and overlapping proteins are displayed.
(G) Volcano plot summarizing the effect of recurrent copy number alterations on the protein abundances of the contained genes (binary data; ANOVA test). Red
and blue points highlight genes with amplifications and losses, respectively. Enlarged points highlight genes at permutation-based FDR < 0.1.
(H) Bar plot illustrating the number of affected proteins by CNAs per genomic locus.
See also Figure S5.mutations is frequent among the COREAD cell lines and repre-
sents a major molecular phenotype.
A less-pronounced impact of LoF mutations was found at the
mRNA level, where only 29 genes (out of 891 with both mRNA
and protein data) exhibited altered mRNA abundances in the
mutated versus the wild-type cell lines at ANOVA test FDR <
0.1 (Figure 3E). The overlap between the protein and mRNA level
analyses is depicted in Figure 3F. Even when we regressed out
the mRNA levels from the respective protein levels, almost
40% of the proteins previously found to be significantly downre-
gulated were recovered at ANOVA test FDR < 0.1 and the
general downregulation trend was still evident (Figure S5C). On
the contrary, regression of protein values out of themRNA values
strongly diminished the statistical significance of the associa-
tions between mutations and mRNA levels (Figure S5D). The
fact that LoF mutations have a greater impact on protein2206 Cell Reports 20, 2201–2214, August 29, 2017abundances compared to the mRNA levels suggests that an
additional post-transcriptional (e.g., translation efficiency) or a
post-translational mechanism (e.g., protein degradation) is
involved in the regulation of the final protein abundances. Lastly,
24 of the genes downregulated at the protein level by LoF muta-
tions have been characterized as essential genes in human colon
cancer cell lines (OGEE database; Chen et al., 2017). Such genes
may be used as targets for negative regulation of cancer cell
fitness upon further inhibition.
We also explored the effect of 20 recurrent copy number
alterations (CNAs), using binary-type data, on the abundances
of 207 quantified proteins falling within these intervals (total
coverage 56%). Amplified genes tended to display increased
protein levels, whereas gene losses had an overall negative
impact on protein abundances with several exceptions (Fig-
ure 3G). The 49 genes for which protein abundance was
associated with CNAs at ANOVA p value < 0.05 (37 genes at
FDR < 0.1) were mapped to 13 genomic loci (Figure 3H), with
13q33.2 amplification encompassing the highest number of
affected proteins. Losses in 18q21.2, 5q21.1, and 17p12 loci
were associated with reduced protein levels of three important
colorectal cancer drivers: SMAD4; APC; and MAP2K4, res-
pectively (FDR < 0.1). Increased levels of CDX2 and HNF4A tran-
scription factors were significantly associated with 13q12.13
and 20q13.12 amplifications (FDR < 0.1). The association of
these transcription factors with a number of targets and meta-
bolic processes as found by the co-variome further reveals the
functional consequences of the particular amplified loci. All
proteins affected by LoF mutations and recurrent CNAs are
annotated in Table S1.
Overall, we show that the protein abundance levels of genes
with mutations predicted to cause nonsense-mediated mRNA
decay are likely to undergo an additional level of negative regu-
lation, which involves translational and/or post-translational
events. The extent of protein downregulation heavily depends
on zygosity and appears to be independent from secondary
structure features and without notable dependency on the
position of the mutation on the encoded product. Missense
mutations rarely affect the protein abundance levels with the sig-
nificant exception of TP53. We conclude that only for a small
portion of the proteome can the variation in abundance be
directly explained by mutations and DNA copy number
variations.
The Consequences of Genomic Alterations Extend to
Protein Complexes
As tightly controlled maintenance of protein abundance appears
to be pivotal for many protein complexes and interactions, we
hypothesize that genomic variation can be transmitted from
directly affected genes to distant gene protein products through
protein interactions, thereby explaining another layer of protein
variation. To assess the frequency of such events, we retrieved
strongly co-varying interactors of the proteins downregulated
by LoF mutations to construct mutation-vulnerable protein net-
works. For stringency, we filtered for known STRING interactions
additionally to the required co-variation. We hypothesize that, in
these subnetworks, the downregulation of a protein node due to
LoF mutations can also lead to the downregulation of interacting
partners. These sub-networks were comprised of 306 protein
nodes and 278 interactions and included at least 10 well-known
protein complexes (Figure 4A). Two characteristic examples
were the BAF and PBAF complexes (Hodges et al., 2016), char-
acterized by disruption of ARID1A, ARID2, and PBRM1 protein
abundances. To confirm whether the downregulation of these
chromatin-remodeling proteins can affect the protein abun-
dance levels of their co-varying interactors (Figure 4B) post-tran-
scriptionally, we performed proteomics and RNA-seq analysis
on CRISPR-Cas9 knockout (KO) clones of these genes in
isogenic human iPSCs (Table S6). We found that downregulation
of ARID1A protein coincided with diminished protein levels of 7
partners in the predicted network (Figure 4C, left panel). These
show the strongest correlations and are known components of
the BAF complex (Hodges et al., 2016). In addition, reduced
levels of ARID2 resulted in the downregulation of three partnersunique to the PBAF complex, with significant loss of PBRM1 pro-
tein (Figure 4C, left panel). Several components of the BAF com-
plex were also compromised in the ARID2 KO, reflecting shared
components of the BAF and PBAF complexes. Conversely, loss
of PBRM1 had no effect on ARID2 protein abundance or any of
its module components, in line with the role of PBRM1 in modi-
fying PBAF targeting specificity (Thompson, 2009). The latter
demonstrates that collateral effects transmitted through protein
interactions can be directional. ARID1A, ARID2, and PBRM1
protein abundance reduction was clearly driven by their respec-
tive lowmRNA levels; however, the effect was not equally strong
in all three genes (Figure 4C, right panel). Strikingly, the interac-
tors that were affected at the protein level were not regulated at
the mRNA level, confirming that the regulation of these protein
complexes is transcript independent (Figure 4C, right panel).
ARID1A KO yielded the highest number of differentially ex-
pressed genes (Figure 4D); however, these changes were poorly
represented in the proteome (Figure 4E). Although pathway-
enrichment analysis in all KOs revealed systematic regulation
of a wide range of pathways at the protein level, mostly affecting
cellular metabolism (Figure 4F), we didn’t identify such regulation
at the mRNA level. This suggests that the downstream effects
elicited by the acquisition of genomic alterations in the particular
genes are distinct between gene expression and protein
regulation.
The latter prompted us to systematically interrogate the
distant effects of all frequent colorectal cancer driver genomic
alterations on protein and mRNA abundances by protein and
gene expression quantitative trait loci analyses (pQTL and
eQTL). We identified 86 proteins and 196 mRNAs with at least
one pQTL and eQTL, respectively, at 10% FDR (Figures 5A
and S5E). To assess the replication rates between independently
tested QTL for each phenotype pair, we also performed the
mapping using 6,456 commonly quantified genes at stringent
(FDR < 10%) andmore relaxed (FDR < 30%) significance cutoffs.
In both instances, we foundmoderate overlap, with 41%–64%of
the pQTL validating as eQTLs and 39%–54% of the eQTLs vali-
dating as pQTL (Figure 5B). Ranking the pQTL by the number of
associations (FDR < 30%) showed that mutations in BMPR2,
RNF43, and ARID1A, as well as CNAs of regions 18q22.1,
13q12.13, 16q23.1, 9p21.3, 13q33.2, and 18q21.2 accounted
for 62% of the total variant-protein pairs (Figure 5C). The
above-mentioned genomic loci were also among the top 10
eQTL hotspots (Figure S5F). High-frequency hotspots in chro-
mosomes 13, 16, and 18 associated with CNAs are consistent
with previously identified regions in colorectal cancer tissues
(Zhang et al., 2014). We next investigated the pQTL for known
associations between the genomic variants and the differentially
regulated proteins. Interestingly, increased protein, but not
mRNA, levels of themediator complex subunits were associated
with FBXW7 mutations (Figure S5G), an ubiquitin ligase that
targets MED13/13L for degradation (Davis et al., 2013).
Overall, our findings indicate that an additional layer of protein
variation can be explained by the collateral effects of mutations
on tightly co-regulated partners in protein co-variation networks.
Moreover, we show that a large portion of genomic variation
affecting gene expression is not directly transmitted to the prote-
ome. Finally, distant protein changes attributed to variation inCell Reports 20, 2201–2214, August 29, 2017 2207
Figure 4. The Consequences of Mutations on Protein Complexes
(A) Correlations networks filtered for known STRING interactions of proteins downregulated by LoF mutations at p value < 0.05. The font size is proportional to
the log10(p value). CORUM interactions are highlighted as green thick edges, and representative protein complexes are labeled.
(B) Protein abundance correlation network of the ARID1A, ARID2, and PBRM1 modules. Green edges denote known CORUM interactions, and the edge
thickness is increasing proportionally to the WGCNA interaction weight.
(C) Heatmap summarizing the protein and mRNA abundance log2fold-change values in the knockout clones compared to the wild-type (WT) clones for the
proteins in the ARID1A, ARID2, and PBRM1 modules.
(D) Volcano plots highlighting the differentially regulated mRNAs in the KO samples.
(E) Scatterplot illustrating the correlation between protein and mRNA abundance changes in the ARID1A KO.
(F) KEGG pathway and CORUM enrichment analysis for the proteomic analysis results of ARID1A, ARID2, and PBRM1CRISPR-cas9 knockouts in human iPSCs.cancer driver genes can be regulated directly at the protein level
with indication of causal effects involving enzyme-substrate
relationships.
Proteomic Subtypes of Colorectal Cancer Cell Lines
To explore whether our deep proteomes recapitulate tissue level
subtypes of colorectal cancer and to provide insight into the
cellular and molecular heterogeneity of the colorectal cancer
cell lines, we performed unsupervised clustering based on the
quantitative profiles of the top 30% most variable proteins
without missing values (n = 2,161) by class discovery using the
ConsensusClusterPlus method (Wilkerson and Hayes, 2010).
Optimal separation by k-means clustering was reached using 5
colorectal proteomic subtypes (CPSs) (Figures S6A and S6B).
Our proteomic clusters overlapped very well with previously
published tissue subtypes and annotations (Medico et al.,2208 Cell Reports 20, 2201–2214, August 29, 20172015; Figure S6C), especially with the classification described
by De Sousa E Melo et al. (2013). Previous classifiers have
commonly subdivided samples along the lines of ‘‘epithelial’’
(lower crypt and crypt top), ‘‘microsatellite instability (MSI)-H,’’
and ‘‘stem-like,’’ with varying descriptions (Guinney et al.,
2015). Our in-depth proteomics dataset not only captures
the commonly identified classification features but provides
increased resolution to further subdivide these groups. The iden-
tification of unique proteomic features pointing to key cellular
functions gives insight into themolecular basis of these subtypes
and provides clarity as to the differences between them (Figures
6A and 6B).
The CPS1 subtype is the canonical MSI-H cluster, overlapping
with theCCS2 cluster identified byDeSousa EMelo et al., (2013),
CMS1 from Guinney et al., (2015), and CPTAC subtype B (Zhang
et al., 2014). Significantly, CPS1 displays low expression of ABC
Figure 5. Proteome-wide Quantitative Trait Loci Analysis of Cancer Driver Genomic Alterations
(A) Identification of cis and trans proteome-wide quantitative trait loci (pQTL) in colorectal cancer cell lines considering colorectal cancer driver variants. The p
value and genomic coordinates for the most confident non-redundant protein-variant association tests are depicted in the Manhattan plot.
(B) Replication rates between independently tested QTL for each phenotype pair using common sets of genes and variants (n = 6,456 genes).
(C) Representation of pQTL as 2D plot of variants (x axis) and associated genes (y axis). Associations with q < 0.3 are shown as dots colored by the beta value
(blue, negative association; red, positive association) while the size is increasing with the confidence of the association. Cumulative plot of the number of as-
sociations per variant is shown below the 2D matrix.
See also Figure S5.transporters, which may lead to low drug efflux and contribute to
the better response rates seen in MSI-H patients (Popat et al.,
2005).
Cell lines with a canonical epithelial phenotype (previously
classified as CCS1 by De Sousa E Melo et al., 2013) clustered
together but are subdivided into 2 subtypes (CPS2 and CPS3).
These subtypes displayed higher expression of HNF4A, indi-
cating a more differentiated state. Whereas subtype CPS3 is
dominated by transit-amplifying cell phenotypes (Sadanandam
et al., 2013), CPS2 is amore heterogeneous group characterized
by a mixed TA and goblet cell signature (Figure S6C). CPS2
is also enriched in lines that are hypermutated, including MSI-
negative/hypermutated lines (HT115, HCC2998, and HT55;
Medico et al., 2015; COSMIC; Figure S6C). However, lower
activation of steroid biosynthesis and ascorbate metabolism
pathways as well as lower levels of ABC transporters in CPS1
render this group clearly distinguishable from CPS2 (Figure 6B).
We also observed subtle differences in the genes mutated
between the two groups. RNF43 mutations and loss of
16q23.1 (including WWOX tumor suppressor) are common in
CPS1. The separation into two distinct MSI-H/hypermutated
classifications was also observed by Guinney et al., (2015) and
may have implications for patient therapy and prognosis.
Transit-amplifying subtype CPS3 can be distinguished from
CPS2 by lower expression of cell cycle proteins (e.g., CDC20,KIF11, and BUB1); predicted low CDK1, CDK2, and PRKACA
kinase activities based on the quantitative profile of known sub-
strates from the PhosphoSitePlus database (Hornbeck et al.,
2015); and high PPAR signaling pathway activation (Figure 6B).
Common amplifications of 20q13.12 and subsequent high
HNF4A levels indicate this cluster corresponds well with CPTAC
subtype E (Figure S6D; Zhang et al., 2014). CPS3 also contains
lines (DIFI and NCI-H508) that are most sensitive to the anti-
epidermal growth factor receptor (EGFR) antibody cetuximab
(Medico et al., 2015).
The commonly observed colorectal stem-like subgroup is
represented by subtypes CPS4 and CPS5 (Figures 6A and
S6C). These cell lines have also been commonly associated
with a less-differentiated state by other classifiers, and this is re-
inforced by our dataset; subtype CPS4 andCPS5 have low levels
of HNF4A and CDX1 transcription factors (Chan et al., 2009;
Garrison et al., 2006; Jones et al., 2015) and correlate well with
CMS4 (Guinney et al., 2015) and CCS3 (De Sousa E Melo et al.,
2013). Cells in CPS4 and CPS5 subtypes commonly exhibit loss
of the 9p21.3 region, including CDKN2A and CDKN2B, whereas
this is rarely seen in other subtypes. Interestingly, whereas
CPS5 displays activation of the Hippo signaling pathway, inflam-
matory/wounding response, and loss of 18q21.2 (SMAD4), CPS4
hasamesenchymal profile,with lowexpressionofCDH1andJUP
similarly toCPTACsubtypeCandhighVimentin. Finally,we foundCell Reports 20, 2201–2214, August 29, 2017 2209
Figure 6. Proteomics Subtypes of Colorectal Cancer Cell Lines and Pathway Analysis
(A) Cell lines are represented as columns, horizontally ordered by five color-coded proteomics consensus clusters and aligned with microsatellite instability (MSI),
HNF4A protein abundance, cancer driver genomic alterations, and differentially regulated proteins.
(B) KEGG pathway and kinase enrichment analysis per cell line.
See also Figure S6.common systematic patterns between the COREAD proteomic
subtypes and the CPTAC colorectal cancer proteomic subtypes
(Zhang et al., 2014) in a global scale (Figures S6D and S6E) using
the cell line signature proteins. The overlap between the cell lines
and the CPTAC colorectal tissue proteomic subtypes is summa-
rized in Figure S6F.
Lastly, we detected 206 differentially regulated proteins
between the MSI-high and MSI-low cell lines (Welch’s t test;
permutation based FDR < 0.1; Figure S7A), which were mainly
converging to downregulation of DNA repair and chromosome
organization as well as to upregulation of proteasome and
Lsm2-8 complex (RNA degradation; Figure S7B). Whereas loss
of DNA repair and organization functions are the underlying
causes of MSI (Boland and Goel, 2010), the upregulation of2210 Cell Reports 20, 2201–2214, August 29, 2017RNA and protein degradation factors indicate the activation
of a scavenging mechanism that regulates the abundance of
mutated gene products.
Pharmacoproteomic Models Significantly Contribute to
Drug Response Prediction
Although a number of recent studies have investigated the power
of different combinations of molecular data to predict drug
response in colorectal cancer cell lines, these have been limited
to using genomic (mutations and copy number), transcriptomic,
and methylation datasets (Iorio et al., 2016). We have shown
above that the DNA and gene expression variations are not
directly consistent with the protein measurements. Also, it has
been shown that there is a gain in predictive power for some
Figure 7. Pharmacoproteomic Models
(A) The number of drugs for which predictive models (i.e., models where the Pearson correlation between predicted and observed IC50s exceeds r > 0.4) could be
fitted is stratified per data type.
(B) Heatmap indicating for each drug and each data type whether a predictive model could be fitted. Most drugs were specifically predicted by one data type.
(C) Heatmap of scaled log2 IC50 values for selected drugs displaying significant association (ANOVA FDR < 0.05) between protein abundance of ABCB1,
ABCB11, and drug response.
(D) Dose-response profiles for colorectal cancer cell lines treated with docetaxel (black line), 2.5 mM tariquidar alone (gray dotted line), or the combination of
docetaxel and 2.5 mM tariquidar (orange line). Error bars represent mean ± SEM.
See also Figure S7.phenotypic associations when also using protein abundance
and phosphorylation changes (Costello et al., 2014; Gholami
et al., 2013; Li et al., 2017). To date, there has not been a compre-
hensive analysis of the effect on the predictive power from the
addition of proteomics datasets in colorectal cancer. All of the
colorectal cell lines included in this study have been extensively
characterized by sensitivity data (half maximal inhibitory concen-
tration [IC50] values) for 265 compounds (Iorio et al., 2016). These
include clinical drugs (n = 48), drugs currently in clinical develop-
ment (n = 76), and experimental compounds (n = 141).
We built Elastic Net models that use as input features
genomic (mutations and copy number gains/losses), methyl-
ation (CpG islands in gene promoters), gene expression, prote-
omics, and phosphoproteomics datasets. We were able to
generate predictive models where the Pearson correlation be-
tween predicted and observed IC50 was greater than 0.4 in 81
of the 265 compounds (Table S7). Response to most drugs
was often specifically predicted by one data type, with very little
overlap (Figures 7A and 7B, respectively). The number of pre-
dictive models per drug target pathway and data type is de-
picted in Figure S7C, highlighting the contribution of proteomics
and phosphoproteomics datasets in predicting response to
certain drug classes.Within the proteomics-based signatures found to be predic-
tive for drug response, we frequently observed the drug efflux
transporters ABCB1 and ABCB11 (6 and 6 out of 24, respec-
tively; 8 non-redundant; Table S7). In all models containing these
proteins, elevated expression of the drug transporter was asso-
ciated with drug resistance, in agreement with previous results
(Garnett et al., 2012). Notably, protein measurements of these
transporters correlated more strongly with response to these
drugs than the respective mRNA measurements (mean Pear-
son’s r = 0.61 and r = 0.31, respectively; Wilcoxon test p value =
0.016). Interestingly, ABCB1 and ABCB11 are tightly co-regu-
lated (Pearson’s r = 0.92), suggesting a novel protein interaction.
Classifying the cell lines into two groups with low and high mean
protein abundance of ABCB1 and ABCB11 revealed a strong
overlap with drug response for 54 compounds (ANOVA test; per-
mutation-based FDR < 0.05). Representative examples of these
drug associations are shown in Figure 7C. To confirm the causal
association between the protein abundance levels of ABCB1,
ABCB11, and drug response, we performed viability assays in
four cell lines treated with docetaxel, a chemotherapeutic agent
broadly used in cancer treatment. The treatments were per-
formed in the presence or absence of an ABCB1 inhibitor (tari-
quidar) and confirmed that ABCB1 inhibition increases sensitivityCell Reports 20, 2201–2214, August 29, 2017 2211
to docetaxel (Figure 7D) in the cell lines with high ABCB1 and
ABCB11 levels. Given the dominant effect of the drug efflux
proteins in drug response, we next tested whether additional
predictive models could be identified by correcting the drug
response data for the mean protein abundance of ABCB1 and
ABCB11 using linear regression. With this analysis, we were
able to generate predictive models for 41 additional drugs
(total 57) from all input datasets combined (Figure S7D;
Table S7). Taken together, our results show that the protein
expression levels of drug efflux pumps play a key role in deter-
mining drug response, and whereas predictive genomic bio-
markers may still be discovered, the importance of proteomic
associations with drug response should not be underestimated.
DISCUSSION
Our analysis of colorectal cancer cells using in-depth proteomics
has yielded several significant insights into both fundamental
molecular cell biology and the molecular heterogeneity of colo-
rectal cancer subtypes. Beyond static measurements of protein
abundances, the quality of our dataset enabled the construction
of a reference proteomic co-variation map with topological
features capturing the interplay between known protein com-
plexes and biological processes in colorectal cancer cells. We
show that the subunits of protein complexes tend to tightly main-
tain their total abundance ratios post-transcriptionally, and this is
a fundamental feature of the co-variation network. The primary
level of co-variation between proteins enables the generation
of unique abundance profiles of known protein interactions,
and the secondary level of co-regulation between protein com-
plexes can indicate the formation of multi-complex protein
assemblies. Moreover, the identification of proteins with outlier
profiles from the conserved profile of their known interactors
within a given complex can point to their pleiotropic roles in
the associated processes. Notably, our approach can be used
in combination with high-throughput pull-down assays (Hein
et al., 2015; Huttlin et al., 2015) for further refinement of large-
scale protein interactomes based on co-variation signatures
that appear to be pivotal for many protein interactions. Addition-
ally, our approach can serve as a time-effective tool for the iden-
tification of tissue-specific co-variation profiles in cancer that
may reflect tissue-specific associations. As a perspective, our
data may be used in combination with genetic interaction
screens (Costanzo et al., 2016) to explore whether protein
co-regulation can explain or predict synthetic lethality (Kaelin,
2005). Another novel aspect that emerged from our analysis is
the maintenance of co-regulation at the level of net protein
phosphorylation. This seems to bemore pronounced in signaling
pathways, where the protein abundances are insufficient to
indicate functional associations. Analogous study of co-regula-
tion between different types of protein modifications could also
enable the identification of modification cross-talk (Beltrao
et al., 2013). This framework also enabled the identification of
upstream regulatory events that link transcription factors to their
transcriptional targets at the protein level and partially explained
the components of the co-variome that are not strictly shaped by
physical protein interactions. To a smaller degree, the module-
based analysis was predictive of DNA copy number variations,2212 Cell Reports 20, 2201–2214, August 29, 2017exposing paradigms of simple cause-and-effect proteogenomic
features of the cell lines. Such associations should be carefully
taken into consideration in large-scale correlation analyses, as
they do not necessarily represent functional relationships.
The simplification of the complex proteomic landscapes into
co-variation modules enables a more direct alignment of
genomic features with cellular functions and delineates how
genomic alterations affect the proteome directly and indirectly.
We show that LoF mutations can have a direct negative impact
on protein abundances further to mRNA regulation. Targeted
deletion of key chromatin modifiers by CRISPR/cas9 followed
by proteomics and RNA-seq analysis confirmed that the effects
of genomic alterations can propagate through physical protein
interactions, highlighting the role of translational or post-transla-
tional mechanisms in modulating protein co-variation. Addition-
ally, our analysis indicated that directionality can be another
characteristic of such interactions.
We provide evidence that colorectal cancer subtypes derived
from tissue level gene expression and proteomics datasets are
largely recapitulated in cell-based model systems at the prote-
ome level, which further resolves the main subtypes into groups.
This classification reflects a possible cell type of origin and
the underlying differences in genomic alterations. This robust
functional characterization of the COREAD cell lines can guide
cell line selection in targeted cellular and biochemical experi-
mental designs, where cell-line-specific biological features can
have an impact on the results. Proteomic analysis highlighted
that the expression of key protein components, such as ABC
transporters, is critical in predicting drug response in colorectal
cancer. Whereas further work is required to establish these
as validated biomarkers of patient response in clinical trials,
numerous studies have noted the role of these channels in aiding
drug efflux (Chen et al., 2016). In summary, this study demon-
strates the utility of proteomics in different aspects of systems
biology and provides a valuable insight into the regulatory varia-
tion in colorectal cancer cells.
EXPERIMENTAL PROCEDURES
Sample Preparation and Analysis
Cell pellets were lysed by probe sonication/boiling, and protein extracts were
subjected to trypsin digestion. The tryptic peptides were labeled with the
TMT10plex reagents, combined at equal amounts, and fractionated with
high-pH C18 high-performance liquid chromatography (HPLC). Phosphopep-
tide enrichment was performed with immobilized metal ion affinity chroma-
tography (IMAC). LC-MS analysis was performed on the Dionex Ultimate
3000 system coupled with the Orbitrap Fusion Mass Spectrometer. MS3
level quantification with Synchronous Precursor Selection was used for total
proteome measurements, whereas phosphopeptide measurements were
obtained with a collision-induced dissociation-higher energy collisional
dissociation (CID-HCD) method at the MS2 level. Raw mass spectrometry
files were subjected to database search and quantification in Proteome
Discoverer 1.4 or 2.1 using the SequestHT node followed by Percolator vali-
dation. Protein and phosphopeptide quantification was obtained by the sum
of column-normalized TMT spectrum intensities followed by row-mean
scaling.
Statistical Analysis
Enrichment for biological terms, pathways, and kinases was performed in
Perseus 1.4 software with Fisher’s test or with the 1D-annotation-enrichment
method. Known kinase-substrate associations were downloaded from the
PhosphoSitePlus database. All terms were filtered for Benjamini-Hochberg
FDR < 0.05 or FDR < 0.1. Correlation analyses were performed in RStudio
with Benjamini-Hochberg multiple testing correction. ANOVA and Welch’s
tests were performed in Perseus 1.4 software. Permutation-based FDR
correction was applied to the ANOVA test p values for the assessment of
the impact of mutations and copy number variations on protein and mRNA
abundances. Volcano plots, boxplots, distribution plots, scatterplots, and
bar plots were drawn in RStudio with the ggplot2 and ggrepel packages. All
QTL associations were implemented by LIMIX using a linear regression test.
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